Genetics Frontiers

Explore breakthrough studies and innovative genomic research

Research Articles

Breaking New Ground in AML Treatment: The CD123-Targeting Therapy Showing Remarkable Promise

Explore the groundbreaking Phase 1b/2 study of IMGN632 in combination with azacitidine and venetoclax for CD123-positive AML patients, featuring promising safety and efficacy results.

Adrian Campbell
Oct 14, 2025

Popular Articles

Research Tags